Frontlight ResearchEarly access
CompletedPhase 2
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
Key facts
- Who runs it
- Sanofi
- Where
- Birmingham, Danbury, Denver, DuBois, Gainesville, Hannibal, Hershey, Houston, Indianapolis, Los Angeles, Maywood, Miami, Minneapolis, New York, Philadelphia, Phoenix, Portland, Sacramento, Salt Lake City, Spartanburg, and Tampa, United StatesSee the 39 sitesAlso in 8 other countries, 28 sites
- Trial code
- NCT05856331
- EU 2023-508084-76-00
- U1111-1309-9066
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 99 people enrolled
- Started
- 12 Oct 2023
- Ended
- 6 Aug 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SAR447537
- Zemaira
- Record updated
- 11 August 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Males or females 18-80 years of age, inclusive, at the time of screening
- Diagnosis of AATD
- Evidence of emphysema secondary to AATD
- FEV1 of ≥ 30% and ≤ 80% predicted at screening
- Current non-smoking status
Who cannot take part
- Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug
- Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days
- On waiting list for lung or liver transplant
- Acute respiratory tract infection or COPD exacerbation within 4 weeks prior to or during screening
- Known or suspected allergy to components of SAR447537 (INBRX-101), A1PI or human IgG
- Known or suspected diagnosis of type 1 diabetes or diagnosed with uncontrolled type 2 diabetes
- Active cancers or has a history of malignancy within 5 years prior to screening
- History of unstable cor pulmonale
- Clinically significant congestive heart failure
- Known selective or severe Immunoglobulin A (IgA) deficiency
- Evidence of decompensated cirrhosis
Where in United States
Also in 8 other countries, 28 sites
- University of Alabama at BirminghamBirmingham, United States
- University of Alabama at Birmingham- Site Number : 105Birmingham, United States
- Western Connecticut Medical GroupDanbury, United States
- National Jewish Medical and Research CenterDenver, United States
- National Jewish Medical and Research Center- Site Number : 123Denver, United States
- Clinical Research Associates Of Central PA , LLC- Site Number : 128DuBois, United States
- Clinical Research Associates of Central Pa, LLCDuBois, United States
- University of FloridaGainesville, United States
- University of Florida College of Medicine- Site Number : 101Gainesville, United States
- Hannibal ClinicHannibal, United States
- Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111Hannibal, United States
- Penn State Health Milton S. Hershey Medical CenterHershey, United States
- Penn State Health Milton S. Hershey Medical Center- Site Number : 122Hershey, United States
- Houston Methodist HospitalHouston, United States
- Houston Methodist Hospital- Site Number : 113Houston, United States
- Indiana UniversityIndianapolis, United States
- David Geffen School of MedicineLos Angeles, United States
- David Geffen School of Medicine- Site Number : 124Los Angeles, United States
- Loyola University Medical CenterMaywood, United States
- Loyola University Medical Center- Site Number : 112Maywood, United States
- Bruce W. Carter Miami VA Medical Center - NAVREF - PPDS- Site Number : 114Miami, United States
- University of MiamiMiami, United States
- M Health Fairview Clinics and Surgery Center - MinneapolisMinneapolis, United States
- M Health Fairview Clinics and Surgery Center - Minneapolis- Site Number : 125Minneapolis, United States
- Columbia University Irving Medical Center- Site Number : 104New York, United States
- Temple University HospitalPhiladelphia, United States
- Temple University Hospital- Site Number : 130Philadelphia, United States
- St Joseph's Hospital and Medical Center- Site Number : 126Phoenix, United States
- St. Joseph's Hospital and Medical CenterPhoenix, United States
- Oregon Health and Science UniversityPortland, United States
- Oregon Health and Science University- Site Number : 117Portland, United States
- UC Davis Comprehensive Cancer Center- Site Number : 110Sacramento, United States
- UC Davis Medical CenterSacramento, United States
- University Of Utah HealthSalt Lake City, United States
- University of Utah Health Care- Site Number : 106Salt Lake City, United States
- Velocity Clinical Research - Spartanburg - PPDSSpartanburg, United States
- Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120Spartanburg, United States
- Pulmonary and Sleep of Tampa BayTampa, United States
- Pulmonary and Sleep of Tampa Bay- Site Number : 115Tampa, United States
About the trial
What the trial wants to find out
Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
The 3 groups in the trial
- SAR447537 (INBRX-101) Q3WTreatment being tested
IV every 3-weeks (Q3W) and placebo (normal saline)
Treatment: SAR447537
- SAR447537 (INBRX-101) Q4WTreatment being tested
IV every 4-weeks (Q4W) and placebo (normal saline)
Treatment: SAR447537
- Zemaira (A1PI)Existing treatment, for comparison
60 mg/kg IV once weekly (QW) and placebo (normal saline)
Treatment: Zemaira
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
- Record updated
- 11 August 2025